Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
IPO Year: 2022
Exchange: NYSE
Website: biohavenpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | $57.00 | Buy | Jefferies |
| 9/4/2024 | $55.00 | Outperform | Bernstein |
| 7/24/2024 | $58.00 | Overweight | Morgan Stanley |
| 2/16/2024 | $62.00 | Outperform | RBC Capital Mkts |
| 2/6/2024 | $59.00 | Buy | UBS |
| 12/22/2023 | $50.00 | Buy | H.C. Wainwright |
| 12/8/2023 | $58.00 | Outperform | Robert W. Baird |
| 1/24/2023 | $24.00 | Outperform | SVB Securities |
| 1/4/2023 | $23.00 | Overweight | JP Morgan |
| 12/2/2022 | $24.00 | Buy | BTIG Research |
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00
Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00
Morgan Stanley initiated coverage of Biohaven with a rating of Overweight and set a new price target of $58.00
RBC Capital Mkts initiated coverage of Biohaven with a rating of Outperform and set a new price target of $62.00
UBS initiated coverage of Biohaven with a rating of Buy and set a new price target of $59.00
H.C. Wainwright initiated coverage of Biohaven with a rating of Buy and set a new price target of $50.00
Robert W. Baird initiated coverage of Biohaven with a rating of Outperform and set a new price target of $58.00
SVB Securities initiated coverage of Biohaven with a rating of Outperform and set a new price target of $24.00
JP Morgan initiated coverage of Biohaven with a rating of Overweight and set a new price target of $23.00
BTIG Research initiated coverage of Biohaven with a rating of Buy and set a new price target of $24.00
8-K - Biohaven Ltd. (0001935979) (Filer)
10-Q - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
424B5 - Biohaven Ltd. (0001935979) (Filer)
424B5 - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
424B7 - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
424B5 - Biohaven Ltd. (0001935979) (Filer)
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 millionAchieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA)Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypesStatistically significant superiority achieved on 9 consecutive, prespecified primary and secondary endpointsBoth the study protocol and statistical analysis plan were submitted to, and reviewed by, the U.S. Food and Drug Admini
NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 6,052,631 of its common shares, which includes the full exercise of the underwriters' option to purchase 789,473 additional common shares, at a public offering price of $47.50 per share. The gross proceeds from the offering were approximately $287.5 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. Biohaven inte
NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 5,263,158 of its common shares at a price to the public of $47.50 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $250 million before deduct
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $250 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $37.5 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and
Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraineBHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational treatment being developed for migraine and other pain disordersDespite recent treatment advances, migraine remains a leading cause of disability and burden, impacting 40 million people in the US and 1 billion world-wideNEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercializat
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300:The Company reported dose-dependent and rapid IgG reductions in its ongoing Phase 1 trial with its lead investigational degrader BHV-1300No serious adverse events (SAEs) reported with BHV-1300 to date; most adverse events (AEs) were mild, deemed unrelated to study drug and resolved spontaneouslyPhase 1 study also completed an assessment of an optimized subcutaneous (
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs across any dose cohorts to dateHighlights advances from novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indicationsRecently initiated a total of 5 pivotal clinical trials with selective Kv7 ac
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price Target of $58.
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Biohaven The Trade: Biohaven Ltd. (NYSE:BHVN) Director John W Childs acquired a total of 28,400 shares at an average price of
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday. Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's session following better-than-expected second-quarter financial results. Net revenue declined 0.8% Y/Y to $12.8 billion, beating the consensus of $12.6 billion. Adjusted EPS rose 4% Y/Y to 82 cents, surpassing the street view of 81 cents, according to data from Benzinga Pro. HP shares climbed 12.5% to $36.94 on Thursday. Here are some other big stocks recording gains in today's session. Latam Logistic Properties, S.A. (NYSE:LPA) shares jumped 61% to $53.35. Foot Locker, Inc. (NYSE:FL) rose 25.9% to $28.35 following a first-quarter earn
Biohaven Ltd’s (NYSE:BHVN) shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven’s lead investigational drug, from its Molecular Degrader of Extracellular Proteins (MoDE) platform. Shares plunged as the data fell short of investor expectations. The drug demonstrated a 30% reduction of Immunoglobulin G (IgG), a type of blood protein, in the 3rd and a 37% reduction in the 4th cohorts within 96 hours. William Blair analyst, writes, “While this is below the high bar for 60% IgG lowering we had heard as a single-dose bogey from many investors, the results for each cohort are in line with the company’s modeling, a
Gainers Innovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million. Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 53.94% to $0.32. The company's market cap stands at $7.5 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 34.56% to $0.27. The company's market cap stands at $4.2 million. Apollomics (NASDAQ:APLM) shares increased by 28.89% to $0.34. The market value of their outstanding shares is at $36.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 25.07% to $0.2. The market value of their outstanding shares is at $4.5 million. Chromocell Therapeuti
Biohaven Ltd. (NYSE:BHVN) stock is moving lower Wednesday. The company recently presented several updates in different fields such as immunology and oncology at its Annual Investor Research and Development Day. The Details: The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. Biohaven started the first patient’s treatment in a Phase 1/2 trial for BHV-1510 which includes subjects with select advanced or metastatic epithelial cell tumors. In addition, Biohaven has entered into a agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) where Biohaven will finance t
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was
Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS(2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS(3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer Fourth-Quarter 2022 Reported Diluted EPS(2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS(3) of $1.14, Up 45% Year-Over-Y
Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the Current Period Related to Tax Resolutions for Multiple Years Impacting Both Reported(2) and Adjusted(3) Diluted EPS Third-Quarter 2022 Adjusted Diluted EPS(3) of $1.78, Reflecting 40% Growth Over Third-Quarter 2021; Excluding Foreign Exchange Impacts, Adjusted Diluted EPS(3) Grew 44% Raises Lower
Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SECNURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57%Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per shareFeatured 31 new and encore presen
Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer's innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus 0.5 of a share of a new publicly traded company that retains Biohaven's non-CGRP pipeline compounds ("New Biohaven") Pfizer and Biohaven to hold analyst call at 10am ET today Pfizer Inc. (NYSE:PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that the companies have entered into a definitive agreement under which Pfi
NEW HAVEN, Conn., May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended March 31, 2022, and provide a review of recent accomplishments and anticipated upcoming milestones, on Wednesday, May 11, 2022 at 8:30 a.m. ET. The earnings call and webcast will follow Biohaven's issuance of its first quarter 2022 earnings release and the filing of its quarterly report on Form 10-Q for the
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones. Vlad Coric, M.D., Chief Executive Officer and Chairman of the Board of Biohaven commented, "Last year was transformative for Biohaven as NURTE
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN, the ", Company", or ", Biohaven", ))) announced today that it has entered into a definitive agreement to acquire Channel Biosciences, LLC, a subsidiary of Knopp Biosciences LLC, and its Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven's growing neuroscience portfolio. The Kv7 platform has been developed and refined for over a decade by a team with deep experience in ion channel science led by Michael Bozik, M.D., and Steven Dworetzky, Ph.D. Both leaders, along with members of their scientific team, are anticipated to join Biohaven as part o
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi
NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy. Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also announced the appointment of Matthew Buten to the role of Chief Financial Officer (CFO) effective by December 20, 2021, following the retirement of CFO James Engelhart. Both Dr. Doogan and Mr. Engelhart will continue
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a mental health focused biotechnology company developing novel psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the addition of several key additions to its leadership team and board of directors. The additions will enable Gilgamesh to rapidly advance its pipeline toward clinical trials beginning in late 2022 and further expand its IP portfolio. Key hires include: Chief Medical Officer Gerard Marek, MD/Ph.D. is a renowned expert on serotonin system biology. Gerard is a former asst. professor at Yale University and was the Chief Scientific Officer of Psychiatric Disorders Discove
NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board"). Mr. Mehta previously served as a strategic advisor to Biohaven. Declan Doogan, M.D., Chairman of Biohaven's Board of Directors, commented, "We are excited to welcome Kishen to Biohaven's Board of Directors and have access to his impressive business and financial acumen to help us continue to excel in achieving our goal of becoming a l